Urine metabolomics for assessing fertility-sparing treatment efficacy in endometrial cancer: a non-invasive approach using ultra-performance liquid chromatography mass spectrometry

Table 2 Prediction ability of metabolite panel for complete remission

Parameter		AUC	Sensitivity	Specificity
^aUrine metabolites panel	Training/Discovery	0.982 (0.931 ~ 1.000)	0.975 (0.953 ~ 0.997)	0.967 (0.940 ~ 0.993)
^aUrine metabolites panel	10-fold Cross-Validation	0.851 (0.722 ~ 0.980)	0.864 (0.864 ~ 1.000)	0.900 (0.769 ~ 1.000)

^aThe urine biomarker panel consisting of Baicalin, 5beta-1,3,7 (11)-Eudesmatrien-8-one, Indolylacryloylglycine, Edulitine, and Physapubenolide

ISSN: 1472-6874